Company intelligence / Profile preview
Sinopharm
- Ownership
- Private
- Development stage
- Other
Overview
Sinopharm has multiple commercialized vaccines (COVID-19, influenza, hepatitis B), and has advanced biologics including an oncolytic virus therapy shown in Nature for hepatocellular carcinoma. Its mRNA herpes zoster vaccine entered clinical trials in 2025.
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- Small moleculeVaccineBiologicMonoclonal antibodyTraditional Chinese medicinemRNA-based drugs
- Industry
- Pharma
Drug pipeline
17 assets16 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $6.8B
- Total revenue
- $86.2B
- Enterprise value
- $12.7B
Beyond the preview
Go deeper on Sinopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinopharm.